Skip to main content
OpenTrials
Completed

NCT Number: NCT01531920

A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel

A Phase 1 study in healthy subjects to determine the safety, tolerability, psychomotor function, and cognitive effects of perampanel when administered alone and with alcohol.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Guildford, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Healthy male and female subjects
  • Females agreed to use two medically acceptable methods of contraception, unless they were surgically sterile
  • Aged 18-55 yrs, inclusive
  • Achieved a Continuous Tracking Test (CTT )score increase of >1.5 pixels from pre-alcohol when dosed with alcohol during the Screening Period (Day minus 8 plus/minus 2 days)
  • Had a current driving license and drove regularly (e.g., more than 1000 miles a year (Part B only)

Exclusion:

  • Any history of significant alcohol abuse or psychiatric disease, requiring inpatient admission or prolonged treatment with psychotropic medication
  • Unable to follow the instructions for the psychometric testing
  • Intolerant to the driving simulator (Part B only)
  • Unable to adhere to long periods of confinement (subjects who could not follow the instructions of the protocol, including the meals)
  • Use of prescription drugs or over-the-counter (OTC) medications within 2 weeks prior to Screening (unless drug had a long half life [i.e., 5 x t 1/2>2 weeks]) with the exception of paracetamol (up to 4 g/day), which was allowed up to 12 hours prior to dosing
  • Had taken any inhibitor of CYP450 within 2 weeks prior to the first dosing (e.g., grapefruit, grapefruit juice, grapefruit-containing beverages, or Seville orange products)
  • Had taken St John's Wort or other dietary aids known to induce CYP3A4 within 4 weeks prior to dosing

Treatment and study plan

alcohol + placebo

Drug

Part A alcohol + placebo

alcohol + perampanel

Drug

Part A: alcohol + perampanel

perampanel + alcohol

Drug

Part B: perampanel + alcohol

placebo + alcohol

Drug

Part B: placebo + alcohol

Primary outcomes

  1. Part A: Changes on Psychomotor Performance (Continuous Tracking Test [CTT]), due to perampanel and alcohol combined and perampanel alone

    Time frame: baseline to Part A Day 1

  2. Part B: Changes on Psychomotor Performance (Continuous Tracking Test [CTT]) due to perampanel and alcohol combined and perampanel alone

    Time frame: baseline to Part B Day 62

  3. Part B:Changes in Cognitive Function due to perampanel and alcohol combined and perampanel alone

    Time frame: baseline to Part B Day 62

  4. Part B: Part B: Changes in driving performance (simulated) due to perampanel and alcohol combined and perampanel alone

    Time frame: Part B Day 34

Secondary outcomes

  1. Part A: Incidence of AEs when perampanel is administered in combination with alcohol

    Time frame: baseline to Part A Day 29

  2. Part B: Incidence of AEs when perampanel is administered in combination with alcohol

    Time frame: baseline to Part B Day 62

Sponsors and collaborators

Lead sponsor

Eisai Limited

Industry

Registry information

Official study title

A Phase 1 Study in Healthy Subjects to Determine the Safety, Tolerability, Psychomotor Function and Cognitive Effects of Perampanel When Administered With Alcohol

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Feb 13, 2012
Registry last updated
Feb 13, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.